18 Nov 2025
Corundum Convergence Institute Welcomes Tracy Laabs and Eric Archambeau to Board of Trustees
Corundum Convergence Institute (CCI), a non-profit venture fueling groundbreaking research at the intersection of neuroscience and systems biology, today announced the appointment of Tracy Laabs, PhD, and Eric Archambeau, PhD to its Board of Trustees.
Dr. Laabs and Dr. Archambeau join CCI as the organization seeks to expand its strategic investments to accelerate the translation of scientific discoveries into real-world applications. Their appointment provides added strategic guidance to strengthen CCI’s research programs, expand collaborative partnerships and accelerate the commercialization of transformative technologies.
“I’m thrilled to join the CCI Board of Trustees and contribute to accelerating neurotechnology from the bench to the bedside,” said Dr. Laabs. “CCI plays a crucial role funding early-stage research and supporting the commercialization of innovative ideas. I’m looking forward to contributing to these efforts.”
Dr. Laabs brings almost two decades of experience in the life sciences, business and technology. She currently serves as Head of Innovation and Strategic Partnerships at the Wyss Center for Bio and Neuroengineering, where she drives growth and investment in the center’s science and technology. She previously served as the center’s Chief Development Officer and Founding Deputy Director, helping establish it as a global leader, scale its portfolio, launch spin-offs and expand its international presence. Prior to joining the Wyss Center, she held several scientific leadership positions at Strategic Analysis Incorporated, was NIH Intramural Fellow at the University of Cambridge and an Associate Research Specialist with the University of Wisconsin-Madison.
"As an advocate for impact investing, I look to fund ventures that are not only financially sound but drive systemic, positive change for the benefit of humanity," said Dr. Archambeau. "I'm excited to join the Board of Trustees, building on our shared vision of supporting ventures that benefit human health, translating promising research into the next generation of truly transformative solutions."
Eric Archambeau is Founder and Managing Partner of Astanor, a global high conviction impact investing firm operating from seed to growth in the bioeconomy sector. A pioneer in impact investing, he has advised global initiatives in social entrepreneurship, regenerative agriculture and sustainable finance, including serving as Global Chairman of the Jamie Oliver Food Foundation and as a board member of the International Foundation for Valuing Impacts. Eric has helped scale startups and established companies, serving on multiple portfolio boards and applying his expertise in product strategy, corporate finance and corporate development.
“We are proud to welcome Dr. Laabs and Dr. Archambeau, both giants in their respective fields, to CCI’s Board of Trustees,” said Shunsuke Nagao, President of Corundum Convergence Institute and CFO of Corundum Systems Biology. “Their collective expertise spanning neurotechnology, impact investing and global collaboration will prove invaluable to our strategic growth. We look forward to working closely with them and our other board members to advance the next generation of cutting-edge research and innovation.”
Dr. Laabs and Dr. Archambeau join CCI as the organization seeks to expand its strategic investments to accelerate the translation of scientific discoveries into real-world applications. Their appointment provides added strategic guidance to strengthen CCI’s research programs, expand collaborative partnerships and accelerate the commercialization of transformative technologies.
“I’m thrilled to join the CCI Board of Trustees and contribute to accelerating neurotechnology from the bench to the bedside,” said Dr. Laabs. “CCI plays a crucial role funding early-stage research and supporting the commercialization of innovative ideas. I’m looking forward to contributing to these efforts.”
Dr. Laabs brings almost two decades of experience in the life sciences, business and technology. She currently serves as Head of Innovation and Strategic Partnerships at the Wyss Center for Bio and Neuroengineering, where she drives growth and investment in the center’s science and technology. She previously served as the center’s Chief Development Officer and Founding Deputy Director, helping establish it as a global leader, scale its portfolio, launch spin-offs and expand its international presence. Prior to joining the Wyss Center, she held several scientific leadership positions at Strategic Analysis Incorporated, was NIH Intramural Fellow at the University of Cambridge and an Associate Research Specialist with the University of Wisconsin-Madison.
"As an advocate for impact investing, I look to fund ventures that are not only financially sound but drive systemic, positive change for the benefit of humanity," said Dr. Archambeau. "I'm excited to join the Board of Trustees, building on our shared vision of supporting ventures that benefit human health, translating promising research into the next generation of truly transformative solutions."
Eric Archambeau is Founder and Managing Partner of Astanor, a global high conviction impact investing firm operating from seed to growth in the bioeconomy sector. A pioneer in impact investing, he has advised global initiatives in social entrepreneurship, regenerative agriculture and sustainable finance, including serving as Global Chairman of the Jamie Oliver Food Foundation and as a board member of the International Foundation for Valuing Impacts. Eric has helped scale startups and established companies, serving on multiple portfolio boards and applying his expertise in product strategy, corporate finance and corporate development.
“We are proud to welcome Dr. Laabs and Dr. Archambeau, both giants in their respective fields, to CCI’s Board of Trustees,” said Shunsuke Nagao, President of Corundum Convergence Institute and CFO of Corundum Systems Biology. “Their collective expertise spanning neurotechnology, impact investing and global collaboration will prove invaluable to our strategic growth. We look forward to working closely with them and our other board members to advance the next generation of cutting-edge research and innovation.”